VANI

Vivani Medical Reports Positive Data From OKV -119 Implant Study To Treat Obesity In Cats

(RTTNews) - Vivani Medical, Inc. (VANI) Tuesday announced positive proof-of-concept weight loss data with OKV-119, a miniature, subdermal, exenatide drug implant designed to treat feline obesity and diabetes. Vivani said the results published in BMC Veterinary Research hold promise in reducing obesity in cats.

Shares are currently at $1.67, down 4.03 percent from the previous close of $1.63 on a volume of 128,256.

The company said its development partner Okava Pharmaceuticals is studying OKV-119 for the treatment of pre-diabetes, diabetes, and obesity in companion felines.

Further, this cat data supports efforts to clinically evaluate its miniature, subdermal GLP-1 implants for the treatment of chronic weight management in obese or overweight human patients and type 2 diabetes, respectively.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.